|
Article Excerpt
The GI Company, Inc., Framingham, Mass., a privately held developer of gastrointestinal therapeutics, has announced that an abstract detailing results from a Phase II clinical trial (2006 - ITF - 009) has been accepted for oral presentation at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). This Phase II study is titled, Prophylaxis of recurrent chemotherapy-induced oral mucositis: A Phase II multicenter, randomized, placebo-controlled trial of recombinant human intestinal trefoil factor (rhITF).
The presentation is scheduled for Monday, June 2, 2008 from 3:30 PM - 3:45 PM in room S100a at McCormick...
|
|
More articles from Biotech Business
OXIGENE BEGINS PHASE II NSCLC TRIAL OF ZYBRESTAT WITH CHEMOTHERAPY., May 01, 2008
Looking for additional articles?
Search our database of over 3 million articles.
Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication
name or publication date.
About Goliath
Whether you're looking for sales prospects, competitive information, company
analysis or best practices in managing your organization,
Goliath can help you meet your business needs.
Our extensive business information databases empower business
professionals with both the breadth and depth of credible,
authoritative information they need to support their business
goals. Whether it be strategic planning, sales prospecting,
company research or defining management best practices -
Goliath is your leading source for accurate information.
|
|
